Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB16076 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB16076, RRID:AB_10676250
- Product name
- BMX polyclonal antibody
- Antibody type
- Polyclonal
- Description
- Rabbit polyclonal antibody raised against synthetic peptide of BMX.
- Storage
- Store at 4°C. For long term storage store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases.
Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking.
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
Nore BF, Mattsson PT, Antonsson P, Bäckesjö CM, Westlund A, Lennartsson J, Hansson H, Löw P, Rönnstrand L, Smith CI
Biochimica et biophysica acta 2003 Feb 21;1645(2):123-32
Biochimica et biophysica acta 2003 Feb 21;1645(2):123-32
Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking.
Yang J, Kim O, Wu J, Qiu Y
The Journal of biological chemistry 2002 Aug 16;277(33):30219-26
The Journal of biological chemistry 2002 Aug 16;277(33):30219-26
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
Qiu Y, Robinson D, Pretlow TG, Kung HJ
Proceedings of the National Academy of Sciences of the United States of America 1998 Mar 31;95(7):3644-9
Proceedings of the National Academy of Sciences of the United States of America 1998 Mar 31;95(7):3644-9
No comments: Submit comment
No validations: Submit validation data